logo
How two satellites are mimicking total solar eclipses in space

How two satellites are mimicking total solar eclipses in space

Associated Press6 hours ago

CAPE CANAVERAL, Fla. (AP) — A pair of European satellites have created the first artificial solar eclipses by flying in precise and fancy formation, providing hours of on-demand totality for scientists.
The European Space Agency released the eclipse pictures at the Paris Air Show on Monday. Launched late last year, the orbiting duo have churned out simulated solar eclipses since March while zooming tens of thousands of miles (kilometers) above Earth.
Flying 492 feet (150 meters) apart, one satellite blocks the sun like the moon does during a natural total solar eclipse as the other aims its telescope at the corona, the sun's outer atmosphere that forms a crown or halo of light.
It's an intricate, prolonged dance requiring extreme precision by the cube-shaped spacecraft, less than 5 feet (1.5 meters) in size. Their flying accuracy needs to be within a mere millimeter, the thickness of a fingernail. This meticulous positioning is achieved autonomously through GPS navigation, star trackers, lasers and radio links.
Dubbed Proba-3, the $210 million mission has generated 10 successful solar eclipses so far during the ongoing checkout phase. The longest eclipse lasted five hours, said the Royal Observatory of Belgium's Andrei Zhukov, the lead scientist for the orbiting corona-observing telescope. He and his team are aiming for a wondrous six hours of totality per eclipse once scientific observations begin.
Scientists already are thrilled by the preliminary results that show the corona without the need for any special image processing, said Zhukov.
'We almost couldn't believe our eyes,' Zhukov said in an email. 'This was the first try, and it worked. It was so incredible.'
Zhukov anticipates an average of two solar eclipses per week being produced for a total of nearly 200 during the two-year mission, yielding more than 1,000 hours of totality. That will be a scientific bonanza since full solar eclipses produce just a few minutes of totality when the moon lines up perfectly between Earth and the sun — on average just once every 18 months.
The sun continues to mystify scientists, especially its corona, which is hotter than the solar surface. Coronal mass ejections result in billions of tons of plasma and magnetic fields being hurled out into space. Geomagnetic storms can result, disrupting power and communication while lighting up the night sky with auroras in unexpected locales.
While previous satellites have generated imitation solar eclipses — including the European Space Agency and NASA's Solar Orbiter and Soho observatory — the sun-blocking disk was always on the same spacecraft as the corona-observing telescope. What makes this mission unique, Zhukov said, is that the sun-shrouding disk and telescope are on two different satellites and therefore far apart.
The distance between these two satellites will give scientists a better look at the part of the corona closest to the limb of the sun.
'We are extremely satisfied by the quality of these images, and again this is really thanks to formation flying' with unprecedented accuracy, ESA's mission manager Damien Galano said from the Paris Air Show.
___
AP journalist John Leicester contributed to this report from Paris.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asciminib: High Responses in Second-Line Chronic-Phase CML
Asciminib: High Responses in Second-Line Chronic-Phase CML

Medscape

timean hour ago

  • Medscape

Asciminib: High Responses in Second-Line Chronic-Phase CML

Asciminib, a first-in-class BCR - ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies. METHODOLOGY: The interim analysis on the single-arm, open-label study, conducted at 85 trial sites in the US, included 101 patients with chronic-phase CML who discontinued a prior TKI due to intolerance or suboptimal responses. Patients were treated with at least one dose of asciminib 80 mg once daily. If BCR - ABL levels were above 1% at week 24, the dose was increased to 200 mg daily, and if BCR - ABL levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. - levels were above 1% at week 24, the dose was increased to 200 mg daily, and if - levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. Those with any grade 3 or 4 or persistent grade 2 toxicities that were refractory to optimal management were ineligible for dose escalations. Reasons for prior treatment discontinuation were due to a lack of efficacy in 56.4% and intolerance in 43.6% of patients. TAKEAWAY: At week 24, a major molecular response was achieved by 44.4% of patients, with 25.4% achieving a deep molecular response (MR4 or better). In all, 11.1% of patients were given dose escalations upon failing to achieve response milestones. Among 101 patients receiving at least one dose, asciminib was well tolerated by most patients. Asciminib's safety profile was that observed in previous studies, with no new or worsening safety findings observed. Grade 3 and higher adverse events (AEs) included hypertension (8.9 %), thrombocytopenia (6.9%), and neutropenia (5.9%). AEs overall led to dose adjustment or interruption in 26.7% of patients and discontinuation in four patients. IN PRACTICE: 'Asciminib, in contrast with other FDA-approved TKIs, binds to the ABL myristoyl pocket, which may reduce off-target effects compared to the other competitive TKI's,' said first author David Jacob Andorsky, MD, of the Rocky Mountain Cancer Centers, US Oncology Research, Boulder, Colorado. 'Results from ASC2ESCALATE, the first prospective trial of asciminib in second-line chronic-phase CML with dose escalation in patients not achieving response milestones, further support asciminib as a treatment option in second-line chronic-phase CML,' he said. 'The outcomes in patients with asciminib dose escalations continue to be explored, with analyses planned for future presentations,' Andorsky noted. SOURCE: The analysis was presented at the American Society of Clinical Oncology (ASCO) 2025 in Chicago. DISCLOSURES: This study was sponsored by Novartis Pharmaceuticals. Andorsky reported having relationships with AbbVie, AstraZeneca, Celgene, and Novartis.

Peter Mohler Named University Of Alabama's New President
Peter Mohler Named University Of Alabama's New President

Forbes

timean hour ago

  • Forbes

Peter Mohler Named University Of Alabama's New President

The University of Alabama has named Peter J. Mohler to be its next president, succeeding Stuart ... More Bell. The University of Alabama System Board of Trustees has unanimously selected Peter J. Mohler to become the 30th president of the University of Alabama, the state's flagship university. He will begin his appointment on July 21, succeeding Stuart Bell, who has been the university's president since 2015. Mohler currently is the executive vice president for research, innovation and knowledge at The Ohio State University and also the chief scientific officer of OSU's Wexner Medical Center. Prior to that, he served for a period as Ohio State's acting president in 2023. 'Dr. Mohler is uniquely equipped to build upon the University of Alabama's strong foundation and lead this institution into an even brighter future,' said UA System Chancellor Sid J. Trant, in a university news release. 'He is a champion for the power of public higher education to transform lives and communities through teaching, research and service, and he will advance our flagship mission through his bold, student-centered and visionary leadership,' added Trant. Mohler is credited with being an advocate for increased educational access and student success, and for supporting programs that promoted stronger graduation outcomes. Mohler earned his bachelor's degree in biology from Wake Forest University and his doctorate in cell and molecular physiology from the University of North Carolina at Chapel Hill. He received a postdoctoral fellowship in the Howard Hughes Medical Institute at Duke University before serving as a faculty member at Vanderbilt University and then later the University of Iowa. A prolific researcher, Mohler has published more than 275 peer-reviewed articles in journals such as Nature, Cell, Nature Medicine, and the New England Journal of Medicine. His research program has been focused on exploring the genetic and cellular mechanisms underlying abnormal heart rhythms and heart failure and developing new diagnostics and therapies for heart disease. Among his many awards, Mohler has been named a Pew Scholar, an Outstanding Investigator of the American Heart Association and an NIH National Heart Lung and Blood Institute Outstanding Investigator. He also has served on the editorial boards of several academic journals. At Ohio State since 2011, Mohler held a number of leadership positions. He served as the director of the Dorothy M. Davis Heart and Lung Research Institute, chair of the department of physiology and cell biology, vice dean of research in the College of Medicine, and vice president for research for the university. Mohler said it was 'a tremendous honor' to be chosen as the next president of the University of Alabama. 'I am deeply grateful to the University of Alabama System Board of Trustees for the opportunity to serve this institution and further its tradition of excellence. UA stands as a national leader in higher education, and I look forward to working collaboratively across campus, the UA System and the state to expand our impact and build on the University's remarkable momentum,' he added. Calling Mohler a 'highly respected and forward-thinking leader,' UA System Board of Trustees President Pro Tempore Scott Phelps said, 'his leadership will attract world-class faculty, staff and students and will ensure they are prepared to thrive and succeed on campus and beyond."

Study finds planetary waves linked to wild summer weather have tripled since 1950
Study finds planetary waves linked to wild summer weather have tripled since 1950

Washington Post

timean hour ago

  • Washington Post

Study finds planetary waves linked to wild summer weather have tripled since 1950

WASHINGTON — Climate change has tripled the frequency of atmospheric wave events linked to extreme summer weather in the last 75 years and that may explain why long-range computer forecasts keep underestimating the surge in killer heat waves, droughts and floods, a new study says. In the 1950s, Earth averaged about one extreme weather-inducing planetary wave event a summer, but now it is getting about three per summer, according to a study in Monday's Proceedings of the National Academy of Sciences. Planetary waves are connected to 2021's deadly and unprecedented Pacific Northwest heat wave , the 2010 Russian heatwave and Pakistan flooding and the 2003 killer European heatwave , the study said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store